TY  - JOUR
AU  - Seymour, John F
AU  - Döhner, Hartmut
AU  - Butrym, Aleksandra
AU  - Wierzbowska, Agnieszka
AU  - Selleslag, Dominik
AU  - Jang, Jun Ho
AU  - Kumar, Rajat
AU  - Cavenagh, James
AU  - Schuh, Andre C
AU  - Candoni, Anna
AU  - Recher, Christian
AU  - Sandhu, Irwindeep
AU  -  Bernal-del-Castillo, Teresa
AU  - Al-Ali, Haifa Kathrin
AU  - Falantes, Jose
AU  - Stone, Richard M
AU  - Minden, Mark D
AU  - Weaver, Jerry
AU  - Songer, Steve
AU  - Beach, C L
AU  - Dombret, Herve
PY  - 2017
DO  - 10.1186/s12885-017-3803-6
UR  - http://hdl.handle.net/10668/11907
T2  - BMC cancer
AB  - Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor...
LA  - en
PB  - BioMed Central Ltd.
KW  - AML
KW  - AML-MRC
KW  - Acute myeloid leukaemia
KW  - Azacitidine
KW  - Induction chemotherapy
KW  - Low-dose cytarabine
KW  - Myelodysplasia-related changes
KW  - Response
KW  - Survival
KW  - Age Factors
KW  - Aged
KW  - Aged, 80 and over
KW  - Antimetabolites, Antineoplastic
KW  - Azacitidine
KW  - Cytarabine
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Myelodysplastic Syndromes
KW  - Prognosis
KW  - Treatment Outcome
TI  - Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
TY  - research article
VL  - 17
ER  -